1-Isopropyl-4-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-1,2,3,6-tetrahydro-pyridine
- $896 - $1388
- Product name: 1-Isopropyl-4-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-1,2,3,6-tetrahydro-pyridine
- CAS: 1642583-50-3
- MF: C14H26BNO2
- MW: 251.17
- EINECS:
- MDL Number:MFCD28098651
- Synonyms:1-Isopropyl-4-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-1,2,3,6-tetrahydro-pyridine;(1-ISOPROPYL-1,2,3,6-TETRAHYDROPYRIDIN-4-YL)BORONIC ACID PINACOL ESTER;Pyridine, 1,2,3,6-tetrahydro-1-(1-methylethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-;1-isopropyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine
2 prices
Selected condition:
Brand
- Crysdot
- Matrix Scientific
Package
- 1g
- ManufacturerCrysdot
- Product numberCD11241814
- Product description1-Isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine 97%
- Packaging1g
- Price$896
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number118459
- Product description1-Isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxa-borolan-2-yl)-1,2,3,6-tetrahydropyridine
- Packaging1g
- Price$1388
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Crysdot | CD11241814 | 1-Isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine 97% | 1g | $896 | 2021-12-16 | Buy |
Matrix Scientific | 118459 | 1-Isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxa-borolan-2-yl)-1,2,3,6-tetrahydropyridine | 1g | $1388 | 2021-12-16 | Buy |
Properties
Boiling point :284.5±50.0 °C(Predicted)
Density :0.97±0.1 g/cm3(Predicted)
pka :9.41±0.40(Predicted)
Density :0.97±0.1 g/cm3(Predicted)
pka :9.41±0.40(Predicted)
Safety Information
Symbol(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|